Basic Casodex Information

• INN (International Nonproprietary Name): Bicalutamide
• Brand Names Available In Australia: Not specified
• ATC Code: L02BB03
• Forms & Dosages: Tablet; strengths 50 mg and 150 mg; blisters of 28, 30, 60, 100; global (prescription only)
• Manufacturers In Australia: Not specified
• Registration Status In Australia: Not specified
• OTC / Rx Classification: Prescription only (Rx)

Latest Research Highlights

Patients and clinicians ask whether bicalutamide still has a role given newer androgen receptor inhibitors.

Recent literature from 2022 to mid‑2024 highlights two clear themes about bicalutamide and Casodex.

First, bicalutamide remains a well‑established first‑generation non‑steroidal anti‑androgen when used alongside LHRH analogues for metastatic prostate cancer.

Second, the landscape is shifting as second‑generation agents such as enzalutamide, apalutamide and darolutamide show superior outcomes in many non‑metastatic and metastatic settings.

Australian registry analyses and TGA adverse‑event summaries continue to report hepatic enzyme elevations and gynecomastia as persistent signals consistent with global safety data.

Real‑world studies in older cohorts report maintained symptom control and PSA suppression with 50 mg daily when combined with LHRH analogues.

Monotherapy at 150 mg remains regionally specific and less commonly used in contemporary practice outside selected locally advanced cases.

Comparative safety work from 2022–24 flags lower central nervous system effects for bicalutamide versus enzalutamide, though bicalutamide is less potent for survival endpoints in several high‑risk trials.

Clinical Effectiveness In Australia

What outcomes do Australian clinicians see with Casodex and bicalutamide?

TGA registration aligns with global authorisations and the drug is used for prostate cancer in line with international practice.

Bicalutamide 50 mg once daily is typically combined with an LHRH analogue for metastatic disease, while 150 mg once daily may be used as monotherapy in selected locally advanced cases, per the available product information.

Australian effectiveness data largely come from hospital oncology units, regional registries and TGA adverse‑event reporting rather than large contemporary randomised trials.

Locally reported outcomes mirror global patterns with PSA reductions and symptomatic improvement most consistently seen in combination therapy with LHRH agents.

Monotherapy benefits at 150 mg appear limited when compared with newer androgen receptor inhibitors for high‑risk disease.

The TGA continues to emphasise liver function surveillance because early ALT/AST rises are the main laboratory signal observed.

Data Highlight:

• TGA adverse events: elevated liver enzymes, gynecomastia, hot flushes reported with frequency consistent with global experience.
• PBS and hospital utilisation: confirm PBS eligibility and local oncology protocols before initiating bicalutamide.

Indications And Expanded Uses

Patients often ask whether Casodex can be used outside standard indications.

Bicalutamide (INN) is indicated for prostate adenocarcinoma as anti‑androgen therapy consistent with the product information.

Typical adult dosing per product information is 50 mg once daily alongside an LHRH analogue for metastatic disease.

Monotherapy at 150 mg once daily is indicated for locally advanced non‑metastatic disease in certain regions and should be confirmed with local guidance.

Off‑label use in Australia is limited and usually restricted to individual circumstances such as intolerance to other agents or constrained access to alternatives.

Expanded or adjuvant uses have become uncommon after 2020 because second‑generation agents demonstrated superior efficacy in many settings.

• Approved Uses: Combination hormonal blockade for metastatic prostate cancer; selected regional monotherapy for locally advanced disease.
• Off‑Label Uses: Rare, case‑by‑case basis where other agents are unsuitable or unavailable.

Definitions:

• Combination Therapy: Bicalutamide 50 mg daily with an LHRH analogue such as goserelin, leuprorelin or triptorelin.
• Monotherapy: Bicalutamide 150 mg daily used alone in selected locally advanced, non‑metastatic cases where regionally authorised.

Always verify TGA and PBS listings and check institutional oncology guidelines before prescribing.

Composition And Brand Landscape

Which brands and packaging options should prescribers and pharmacists expect?

The active ingredient is bicalutamide (INN), with the originator brand Casodex supplied by AstraZeneca.

Major generics identified globally include Cipla, Intas and R‑Pharm, with local licensees in various markets.

Available dosage forms from the product information are 50 mg and 150 mg film‑coated tablets, commonly packed in blisters of 28, 30, 60 or 100 tablets.

In Australia, Casodex is the recognised brand name, and generics may be available via import or local licences; check the TGA ARTG and PBS listings for current entries.

For patients: the medicine is prescription‑only, store below 25°C and keep in the original packaging until use.

Pharmacy channels such as Chemist Warehouse, Priceline and TerryWhite Chemmart typically dispense on a prescription, and online/telehealth supply is possible with a valid e‑prescription.

Contraindications And Special Precautions

Which patients must avoid Casodex and who needs closer monitoring?

Absolute contraindications include women and children, known hypersensitivity to bicalutamide or any excipient, and severe hepatic impairment.

Relative cautions apply for mild‑to‑moderate hepatic disease and prior exposure to hepatotoxic medicines.

Concomitant use with narrow‑therapeutic‑index medicines such as warfarin requires caution and close monitoring.

Elderly patients do not usually need dose adjustment, but comorbidity and polypharmacy increase risk and warrant careful review.

Special Australian considerations include higher prevalence of chronic liver disease in some Indigenous communities, which calls for extra vigilance and culturally safe counselling.

Remote patients may need coordinated pathology access to ensure timely liver function tests.

Daily‑life precautions: counsel patients about possible fatigue, dizziness and potential impact on driving or operating heavy machinery.

Advise minimising alcohol because it increases hepatic strain and may amplify liver injury risk.

Checklist:

• Contraindicated: women, children, severe hepatic impairment, hypersensitivity.
• Use with caution: mild‑moderate liver disease, prior hepatotoxins, warfarin co‑administration.

Dosage Guidelines

How should bicalutamide be dosed and monitored in routine practice?

Standard regimens per product information are 50 mg once daily alongside an LHRH analogue for metastatic prostate cancer.

Selected locally advanced cases may use 150 mg once daily as monotherapy where authorised regionally.

No routine dose adjustment is required for elderly patients, while moderate to severe hepatic impairment is a situation to avoid or use with extreme caution.

Missed dose advice: take as soon as remembered unless it is close to the next scheduled dose; do not double up.

Overdose management is supportive only and requires urgent medical review since no specific antidote exists.

Typical treatment duration is indefinite for metastatic disease until progression or unacceptable toxicity, and at least two years or per protocol for some locally advanced regimens.

Pharmacists and prescribers should keep a short regimen checklist for adherence counselling and monitoring tasks.

Interactions Overview

What drug combinations require extra caution with Casodex?

Bicalutamide is metabolised hepatically and interactions arise with medicines that alter liver enzymes or have narrow therapeutic indices.

Particular caution is flagged with warfarin because bicalutamide may alter INR, so frequent monitoring is advised when co‑prescribed.

Concurrent hepatotoxic drugs increase the risk of liver injury and should be avoided where possible.

Alcohol misuse further increases hepatotoxicity potential and should be minimised.

Second‑generation AR antagonists have differing interaction profiles and CNS risks, but hepatic pathways overlap for metabolic interactions in some cases.

For rural Australian patients on multiple chronic medicines, use e‑health medication lists and clinical decision support to check interactions and coordinate INR and LFT monitoring.

Cultural Perceptions And Patient Habits

How do Australian patients view Casodex and what practical issues affect adherence?

Many users trust community pharmacists at chains such as Chemist Warehouse and TerryWhite for practical medicine information.

Cost and PBS subsidy status are decisive for patients and often drive the choice between older agents like bicalutamide and newer alternatives.

Rural populations may face delayed pathology access and rely on telehealth e‑prescriptions with local pharmacy dispense arrangements.

Regional oncologists sometimes favour older, more accessible agents where newer drugs are not PBS‑subsidised or affordable.

Indigenous patients may have concerns about medication safety, interactions with traditional practices and higher comorbidity such as chronic liver disease.

Culturally safe counselling and involvement of community health workers are essential for these communities.

Online forums commonly discuss gynecomastia, hot flushes and medicine cost, so clinicians should proactively address these topics in counselling.

Availability And Pricing Patterns

Where can patients get Casodex and how much might it cost?

Casodex by AstraZeneca is the recognised brand and generics may be sourced via import or local licences per the supplier landscape.

Dispensing in Australia occurs through major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart, and through accredited online pharmacies that accept valid e‑prescriptions.

Pricing varies markedly between PBS‑subsidised dispensing and private prescriptions for non‑PBS formulations, so always confirm PBS listing and authority requirements before prescribing.

Rural pharmacies may experience stock delays, and patients should be advised to allow extra time for repeat supplies or use pharmacy delivery networks.

Storage and transport guidance is to store below 25°C and keep the medicine in its original packaging during transport.

In our online pharmacy, casodex is available without a prescription, with discreet delivery to Australia in 5-14 days.

Prescribers should verify PBS eligibility, authority requirements and local stock before finalising a treatment plan.

Comparable Medicines And Preferences

Which alternatives should clinicians consider when selecting hormonal therapy?

Main comparators include first‑generation anti‑androgens flutamide and nilutamide and second‑generation agents enzalutamide, apalutamide and darolutamide.

Advantages of bicalutamide include oral dosing, generally good tolerability for many patients and lower CNS side effects than enzalutamide.

Disadvantages are lower potency for survival endpoints compared with several modern agents and ongoing risks of gynecomastia and hepatic enzyme elevations.

In Australia, PBS subsidy status, cost, comorbidities (especially liver disease) and the risk of CNS effects influence agent selection more than theoretical efficacy alone.

A pros and cons checklist and decision matrix helps pharmacists and prescribers support shared decision‑making tailored to each patient.

Frequently Asked Questions

Is Casodex on the PBS?

PBS listings can change and prescribers should check the current PBS schedule and any authority requirements.

How should Casodex be taken?

Usually once daily by mouth; 50 mg with an LHRH analogue for metastatic disease and 150 mg monotherapy in selected locally advanced cases where authorised.

What side effects should be reported urgently?

Report new jaundice, severe abdominal pain, persistent nausea, marked fatigue, unusual bruising or bleeding, or significant mood or CNS changes for urgent review and LFT/INR checks if on warfarin.

Can alcohol be consumed?

Alcohol should be limited as it increases hepatic risk while taking bicalutamide.

Definitions:

• PSA: Prostate‑specific antigen, a blood marker used to monitor prostate cancer.
• LHRH: Luteinising hormone‑releasing hormone analogues used to suppress testosterone production.

Guidelines For Proper Use

What should pharmacists cover when counselling patients starting Casodex?

Confirm the indication and review the full medication list, with attention to warfarin and other hepatotoxics.

Advise dosing clearly: 50 mg daily with an LHRH analogue, or 150 mg daily as monotherapy where authorised regionally.

Emphasise liver‑function monitoring with baseline tests and monthly checks for the first three months unless local oncology protocols state otherwise.

Encourage adherence and explain missed‑dose rules and storage below 25°C in the original pack.

For telehealth and rural patients, arrange local pathology access and coordinate medicine delivery or local dispensing.

Escalation triggers for urgent review include symptoms of liver injury, marked bleeding while on anticoagulants, or new psychiatric/CNS events.

Document PBS authority details where relevant and report adverse events to the TGA.

Pharmacist Counselling Script (One Page):

• Confirm patient understands indication and dosing schedule.
• Advise baseline LFTs and monthly monitoring for the first three months.
• Check interactions, especially with warfarin; advise additional INR checks.
• Warn about gynecomastia, hot flushes and common GI effects; provide symptomatic advice.
• Arrange delivery or local pharmacy pick up and provide contact details for urgent concerns.

Delivery Across Australia